These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23930800)

  • 1. Immune alterations in malignant melanoma and current immunotherapy concepts.
    Shimanovsky A; Jethava A; Dasanu CA
    Expert Opin Biol Ther; 2013 Oct; 13(10):1413-27. PubMed ID: 23930800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer developments in the immunotherapy of malignant melanoma.
    Maslin B; Alexandrescu DT; Ichim TE; Dasanu CA
    J Oncol Pharm Pract; 2014 Feb; 20(1):3-10. PubMed ID: 23435643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune alterations and emerging immunotherapeutic approaches in lung cancer.
    Dasanu CA; Sethi N; Ahmed N
    Expert Opin Biol Ther; 2012 Jul; 12(7):923-37. PubMed ID: 22559147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
    Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
    Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.
    Ascierto PA; Kalos M; Schaer DA; Callahan MK; Wolchok JD
    Clin Cancer Res; 2013 Mar; 19(5):1009-20. PubMed ID: 23460532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1 therapy in melanoma.
    Homet Moreno B; Parisi G; Robert L; Ribas A
    Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for metastatic melanoma.
    Zito CR; Kluger HM
    J Cell Biochem; 2012 Mar; 113(3):725-34. PubMed ID: 22006439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of metastatic melanoma: new immunomodulatory agents.
    Sznol M
    Semin Oncol; 2012 Apr; 39(2):192-203. PubMed ID: 22484191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Are immunological treatments beneficial for malignant melanoma of the skin?].
    Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
    Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Possibilities of immunotherapy in malignant melanoma].
    Lewis MG
    Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunology and therapy of malignant melanoma (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1977 Sep; 89(18):612-22. PubMed ID: 906525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
    Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
    Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for metastatic malignant melanoma: old drugs and new strategies.
    Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic microenvironment and personalized treatment in multiple myeloma.
    Rossi M; Botta C; Correale P; Tassone P; Tagliaferri P
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S83-93. PubMed ID: 23692463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.
    O'reilly A; Larkin J
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):647-655. PubMed ID: 28604130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma immunotherapy.
    Sanlorenzo M; Vujic I; Posch C; Dajee A; Yen A; Kim S; Ashworth M; Rosenblum MD; Algazi A; Osella-Abate S; Quaglino P; Daud A; Ortiz-Urda S
    Cancer Biol Ther; 2014 Jun; 15(6):665-74. PubMed ID: 24651672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.